In the AR-high setting where AR repressed ERα signaling, enzalutamide antagonized AR, promoting ERα signaling, while RAD140, a selective AR agonist, activated AR signaling and suppressed AR-high tumor growth by inhibiting ER52. Here, AR is linked to neoplasm.